Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology
+$0.41 today
- Market cap
- $3.65B
- Beta
- 1.75
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$1.52
Volume 2.43M
Average 3.70M
RLAY Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Relay Therapeutics, Inc.NASDAQ: RLAY
Operating Margin · Q2 FY2026 · quarter ended Jun 2026
Operating margin narrows to -25949.7%
Operating margin was -25949.7% in Q2 FY2026, down 14598.6 pp from a year earlier. On a trailing-twelve-month basis it was -2999.4%, up 1106.2 pp year over year. Over 3 fiscal years it widened by 19699.3 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 8 analysts of -2722.8% for the fiscal year ending Dec 2026, down from -1971.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -25949.7%-23330.0 pp QoQ
- Last fiscal yearDec 2025
- -1971.6%+1750.5 pp YoY
- LTMJun 2026
- -2999.4%+1106.2 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1971.6%
- Year-over-year change
- +1750.5pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1971.6% | +1750.5pp |
| FY2024 | 2024-12-31 | -3722.1% | -2262.0pp |
| FY2023 | 2023-12-31 | -1460.1% | +20210.8pp |
| FY2022 | 2022-12-31 | -21670.9% | -9630.7pp |
| FY2021 | 2021-12-31 | -12040.2% | — |
Operating Margin vs competitors
How RLAY compares with its peers on the latest reported figures
- RLAY's LTM Jun 2026 operating margin of -2999.4% is the lowest of the 6 companies compared; the peer median is -178.4%.
- Its year-over-year change of +1106.2 pp is the 3rd highest of 6, against a peer median of +364.0 pp.
- Over three fiscal years its change of +19699.3 pp compares with a peer median of +92.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 41.3% | +360.6 pp | +135.8 pp | |
| LTM Mar 2026 | -81.4% | +5066.4 pp | +49.9 pp | |
| FY2025 | -178.4% | +167.7 pp | +268.4 pp | |
| LTM Jun 2026 | -333.5% | +364.0 pp | -547.0 pp | |
| LTM Mar 2026 | -503.2% | +1496.5 pp | — | |
| LTM Jun 2026 | -2999.4% | +1106.2 pp | +19699.3 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding RLAY) | -178.4% | +364.0 pp | +92.9 pp | |
Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.03M | 1.38M | 25.55M | 10.01M | 15.36M |
| Cost of Revenue | 169.39M | 243.01M | 326.39M | 315.44M | 3.56M |
| Gross Profit | (166.36M) | (241.62M) | (300.84M) | (305.43M) | 11.8M |
| Gross Margin | -5492.2% | -17496.3% | -1177.6% | -3052.2% | 76.8% |
| Research & Development | 295.65M | 246.36M | 330.02M | 319.09M | 261.38M |
| Selling, General & Admin | 59.75M | 69.33M | 78.58M | 80.24M | 56.71M |
| Operating Expenses | 198.34M | 57.65M | 72.16M | 67.03M | 314.54M |
| Depreciation & Amortization | 3.93M | 4.13M | 5.27M | 5.46M | 3.56M |
| EBITDA | (223.08M) | (306.82M) | (374.15M) | (380.21M) | (272.92M) |
| EBITDA Margin | -7364.9% | -22217.4% | -1464.6% | -3799.4% | -1777.4% |
| Operating Income | (364.7M) | (299.28M) | (373M) | (372.47M) | (302.74M) |
| Operating Margin | -12040.2% | -21670.9% | -1460.1% | -3722.1% | -1971.6% |
| Interest Income | 830K | 8.79M | 31.05M | 34.75M | 27.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 826K | 8.77M | 31.03M | 34.76M | 26.26M |
| Income Before Tax | (363.87M) | (290.51M) | (341.97M) | (337.71M) | (276.48M) |
| Pre-Tax Margin | -12012.9% | -21036.1% | -1338.7% | -3374.7% | -1800.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (363.87M) | (290.51M) | (341.97M) | (337.71M) | (276.48M) |
| Net Margin | -12012.9% | -21036.1% | -1338.7% | -3374.7% | -1800.6% |
| EPS (Basic) | (3.82) | (2.59) | (2.79) | (2.36) | (1.61) |
| EPS (Diluted) | (3.82) | (2.59) | (2.79) | (2.36) | (1.61) |
| Weighted Avg Shares | 95.14M | 112.23M | 122.58M | 142.87M | 171.59M |
| Weighted Avg Shares (Diluted) | 95.14M | 112.23M | 122.58M | 142.87M | 171.59M |
Relay Therapeutics, Inc.
NASDAQ:RLAY
Intrinsic Alpha fair value
Locked
Current Price
$16.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.